Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: A multicentre audit

Tan N. Doan, Carl M.J. Kirkpatrick, Patricia Walker, Monica A. Slavin, Michelle R. Ananda-Rajah, C. Orla Morrissey, Karen F. Urbancic, Andrew P Grigg, Andrew Spencer, Jeffrey Szer, John Francis Seymour, David C. M. Kong

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

Objectives: The primary objectives were to investigate the prescribing practices of primary antifungal prophylaxis (PAP) and incidence of invasive fungal disease (IFD) in adult patients with ALL receiving induction-consolidation chemotherapy. Secondary objectives were to determine risk factors for IFD and resource utilization associated with IFD. Methods: A retrospective chart review of adult patients with ALL from commencement of induction until completion of consolidation chemotherapy was undertaken from January 2008 to June 2013 in four hospitals in Melbourne, Australia. IFD was classified according to the revised European Organisation for Research and Treatment of Cancer criteria. Cost analysis was performed from an Australian public hospital perspective. Results: Ninety-eight patients were included in the audit; 83 (85%) received PAP. Most patients (49/83, 59%) switched between two different antifungal agents, predominantly between liposomal amphotericin B and an azole. Five proven/probable and six possible IFD cases were identified. Proven/probable IFD was most common in patients receiving the BFM95 chemotherapy protocol. The incidence of proven/probable IFD was significantly lower in patients receiving PAP compared with those who did not (2/78, 2.6% versus 3/14, 21.4%; P = 0.024). For every five patients receiving PAP, one proven/probable IFD case would be prevented. Proven/probable IFD was associated with an additional median cost of 121 520 Australian dollars (95% CI: 90 781-180 141 Australian dollars; P < 0.001) compared with patients without IFD. Conclusions: This is the first multicentre study evaluating PAP use in patients with ALL. With the caveats of interpretation of retrospective, non-randomized data, PAP was associated with a reduced IFD risk.

Original languageEnglish
Article numberdkv343
Pages (from-to)497-505
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume71
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016

Cite this

Doan, Tan N. ; Kirkpatrick, Carl M.J. ; Walker, Patricia ; Slavin, Monica A. ; Ananda-Rajah, Michelle R. ; Morrissey, C. Orla ; Urbancic, Karen F. ; Grigg, Andrew P ; Spencer, Andrew ; Szer, Jeffrey ; Seymour, John Francis ; Kong, David C. M. / Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia : A multicentre audit. In: Journal of Antimicrobial Chemotherapy. 2016 ; Vol. 71, No. 2. pp. 497-505.
@article{a59d2a634d88483193ce98f778396e44,
title = "Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: A multicentre audit",
abstract = "Objectives: The primary objectives were to investigate the prescribing practices of primary antifungal prophylaxis (PAP) and incidence of invasive fungal disease (IFD) in adult patients with ALL receiving induction-consolidation chemotherapy. Secondary objectives were to determine risk factors for IFD and resource utilization associated with IFD. Methods: A retrospective chart review of adult patients with ALL from commencement of induction until completion of consolidation chemotherapy was undertaken from January 2008 to June 2013 in four hospitals in Melbourne, Australia. IFD was classified according to the revised European Organisation for Research and Treatment of Cancer criteria. Cost analysis was performed from an Australian public hospital perspective. Results: Ninety-eight patients were included in the audit; 83 (85{\%}) received PAP. Most patients (49/83, 59{\%}) switched between two different antifungal agents, predominantly between liposomal amphotericin B and an azole. Five proven/probable and six possible IFD cases were identified. Proven/probable IFD was most common in patients receiving the BFM95 chemotherapy protocol. The incidence of proven/probable IFD was significantly lower in patients receiving PAP compared with those who did not (2/78, 2.6{\%} versus 3/14, 21.4{\%}; P = 0.024). For every five patients receiving PAP, one proven/probable IFD case would be prevented. Proven/probable IFD was associated with an additional median cost of 121 520 Australian dollars (95{\%} CI: 90 781-180 141 Australian dollars; P < 0.001) compared with patients without IFD. Conclusions: This is the first multicentre study evaluating PAP use in patients with ALL. With the caveats of interpretation of retrospective, non-randomized data, PAP was associated with a reduced IFD risk.",
author = "Doan, {Tan N.} and Kirkpatrick, {Carl M.J.} and Patricia Walker and Slavin, {Monica A.} and Ananda-Rajah, {Michelle R.} and Morrissey, {C. Orla} and Urbancic, {Karen F.} and Grigg, {Andrew P} and Andrew Spencer and Jeffrey Szer and Seymour, {John Francis} and Kong, {David C. M.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1093/jac/dkv343",
language = "English",
volume = "71",
pages = "497--505",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia : A multicentre audit. / Doan, Tan N.; Kirkpatrick, Carl M.J.; Walker, Patricia; Slavin, Monica A.; Ananda-Rajah, Michelle R.; Morrissey, C. Orla; Urbancic, Karen F.; Grigg, Andrew P; Spencer, Andrew; Szer, Jeffrey; Seymour, John Francis; Kong, David C. M.

In: Journal of Antimicrobial Chemotherapy, Vol. 71, No. 2, dkv343, 01.02.2016, p. 497-505.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia

T2 - A multicentre audit

AU - Doan, Tan N.

AU - Kirkpatrick, Carl M.J.

AU - Walker, Patricia

AU - Slavin, Monica A.

AU - Ananda-Rajah, Michelle R.

AU - Morrissey, C. Orla

AU - Urbancic, Karen F.

AU - Grigg, Andrew P

AU - Spencer, Andrew

AU - Szer, Jeffrey

AU - Seymour, John Francis

AU - Kong, David C. M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objectives: The primary objectives were to investigate the prescribing practices of primary antifungal prophylaxis (PAP) and incidence of invasive fungal disease (IFD) in adult patients with ALL receiving induction-consolidation chemotherapy. Secondary objectives were to determine risk factors for IFD and resource utilization associated with IFD. Methods: A retrospective chart review of adult patients with ALL from commencement of induction until completion of consolidation chemotherapy was undertaken from January 2008 to June 2013 in four hospitals in Melbourne, Australia. IFD was classified according to the revised European Organisation for Research and Treatment of Cancer criteria. Cost analysis was performed from an Australian public hospital perspective. Results: Ninety-eight patients were included in the audit; 83 (85%) received PAP. Most patients (49/83, 59%) switched between two different antifungal agents, predominantly between liposomal amphotericin B and an azole. Five proven/probable and six possible IFD cases were identified. Proven/probable IFD was most common in patients receiving the BFM95 chemotherapy protocol. The incidence of proven/probable IFD was significantly lower in patients receiving PAP compared with those who did not (2/78, 2.6% versus 3/14, 21.4%; P = 0.024). For every five patients receiving PAP, one proven/probable IFD case would be prevented. Proven/probable IFD was associated with an additional median cost of 121 520 Australian dollars (95% CI: 90 781-180 141 Australian dollars; P < 0.001) compared with patients without IFD. Conclusions: This is the first multicentre study evaluating PAP use in patients with ALL. With the caveats of interpretation of retrospective, non-randomized data, PAP was associated with a reduced IFD risk.

AB - Objectives: The primary objectives were to investigate the prescribing practices of primary antifungal prophylaxis (PAP) and incidence of invasive fungal disease (IFD) in adult patients with ALL receiving induction-consolidation chemotherapy. Secondary objectives were to determine risk factors for IFD and resource utilization associated with IFD. Methods: A retrospective chart review of adult patients with ALL from commencement of induction until completion of consolidation chemotherapy was undertaken from January 2008 to June 2013 in four hospitals in Melbourne, Australia. IFD was classified according to the revised European Organisation for Research and Treatment of Cancer criteria. Cost analysis was performed from an Australian public hospital perspective. Results: Ninety-eight patients were included in the audit; 83 (85%) received PAP. Most patients (49/83, 59%) switched between two different antifungal agents, predominantly between liposomal amphotericin B and an azole. Five proven/probable and six possible IFD cases were identified. Proven/probable IFD was most common in patients receiving the BFM95 chemotherapy protocol. The incidence of proven/probable IFD was significantly lower in patients receiving PAP compared with those who did not (2/78, 2.6% versus 3/14, 21.4%; P = 0.024). For every five patients receiving PAP, one proven/probable IFD case would be prevented. Proven/probable IFD was associated with an additional median cost of 121 520 Australian dollars (95% CI: 90 781-180 141 Australian dollars; P < 0.001) compared with patients without IFD. Conclusions: This is the first multicentre study evaluating PAP use in patients with ALL. With the caveats of interpretation of retrospective, non-randomized data, PAP was associated with a reduced IFD risk.

UR - http://www.scopus.com/inward/record.url?scp=84959883541&partnerID=8YFLogxK

U2 - 10.1093/jac/dkv343

DO - 10.1093/jac/dkv343

M3 - Article

C2 - 26518050

AN - SCOPUS:84959883541

VL - 71

SP - 497

EP - 505

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

M1 - dkv343

ER -